1 General Aspects

20 General Aspects

9 References 1. Ash D. Interstitial and endoluminal radiation therapy. In: Souhami RL, Tannock I, Hohenberger P, Horiot GC (eds). Oxford book of Oncology (2 nd Edition ) 2002; Oxford-New York: Oxford University Press: 433-43. 2. Auer T, Hensler E, Eichberger P, et al. 3D navigation for interstitial stereotaxic brachytherapy. Strahlenth Onkol 1998; 174 : 82-7. 3. Baltas D, Kolotas C, Geramini KG. A conformal index (coin) to evaluate implant quality and dose specification in brachytherapy. Int J Radiat Oncol Biol Phys 1998; 40 : 515-24. 4. Brenner DJ. Radiation biology in brachytherapy. J Surg Oncol 1997; 65 : 66-70. 5. Chassagne D, Sismondi P, Horiot JC, et al. A glossary for reporting complications of the treatment in gynaecological cancers. Radiother Oncol 1993; 26 : 195-202. 6. Dale RG, Jones B. The clinical radiobiology of brachytherapy. Br J Radiol 1998; 71 : 465-83. 7. Dobbs J, Barrett A, Ash D (eds.). Practical Radiotherapy Planning (3 rd Edition) 1999; London: Arnold. 8. Dutreix A, Marinello G, Wambersie A. Dosimetrie en curietherapie 1982; Paris: Masson. 9. Dutreix A. Can we compare systems for interstitial therapy? Radiother Oncol 1989; 15 : 25-37. 10. Dutreix J, Tubiana M, Pierquin B. The hazy dawn of brachytherapy. Radiother Oncol 1998; 49 : 223- 32. 11. Erickson B, Wilson F. Clinical indications for brachytherapy. J Surg Oncol , 1997: 65 : 218-27. 12. Fowler JF, Van Limbergen E. Biological effect of pulsed dose rate brachytherapy with stepping sources if short half-times of repair are present in tissues. Int J Radiat Oncol Biol Phys 1997; 37 : 377-83. 13. Gerbaulet A, Baldeyrou P, Chirat E, et al. Quelle curietherapie pour quel type de cancer. Imp Med Hebdo (les dossiers du praticien) 1996; 3 : 319-23. 14. Gerbaulet AP. Quel avenir pour la curietherapie. Cancer Radiother 1999; 3 (suppl. 1): 19-29. 15. Henschke U, Hilaris BS, Mahan GD. Afterloading in interstitial and intracavitary radiation therapy. Am J Roentgenol 1963; 90 : 386-95. 16. ICRU. Dose and volume specification for reporting interstitial therapy. ICRU Report 58 1997; Bethesda: International Commission on Radiation Units and measurements. 17. ICRU. Dose and volume specification for reporting intracavitary therapy in gynecology. ICRU Report 38 1985; Washington: International Commission on Radiation Units and measurements. 18. Joslin CAF, Flyn A, Hall EJ (eds.). Principles and practice of brachytherapy 2001; London: Arnold. 19. Joslin CAF. The future of brachytherapy. In: Mould RF, Batterman JJ, Martinez AA, Speizer BL (eds.) Brachytherapy: from radium to optimization. Veenendaal The Netherlands. Nucletron International 1994; 415-24. 20. Martel MK, Narayana V. Brachytherapy for the next century: use of image-based treatment planning. Radiat Res 1998; 150 : 178-88. 21. Mazeron JJ, Gerbaulet A, Simon JM, Hardiman C. How to optimise therapeutic ratio in brachytherapy of head and neck squamous cell carcinoma? Actual Oncol 1998; 37 : 583-91. 22. Mazeron JJ, Gerbaulet A. Le centenaire de la decouverte du radium. Cancer Radiother 1999; 3 : 19- 29. 23. Meertens H, Borger J, Stettgerda M, Blom A. Evaluation and optimisation of interstitial brachytherapy dose distribution. In: Mould RF, Battermann JJ, Martinez AA, Speizer BL (eds.) Brachytherapy: from radium to optimization. Veenendaal The Netherlands. Nucletron International 1994. 300-7 24. Meredith WJ. Radium Dosage: The Manchester System. Edinburgh: Livingston 1967. 25. Mould RF, Battermann JJ, Martinez AA, Speiser BL (eds.). Brachytherapy: from radium to optimization. Veenendaal The Netherlands. Nucletron International 1994. 26. Nag S. Principles and practice of brachytherapy 1997. New York: Futura Publishing Company.